Pages that link to "Q45728977"

The following pages link to Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection (Q45728977):

Displaying 20 items.

• Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review (Q34726169) (← links)
• Palivizumab for preterm infants. Is it worth it? (Q35296973) (← links)
• Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention (Q35735115) (← links)
• Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection (Q35788059) (← links)
• Demystified...recombinant antibodies (Q35873117) (← links)
• Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. (Q37217409) (← links)
• Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV) (Q37290618) (← links)
• Prevention of respiratory syncytial virus infection (Q37429454) (← links)
• Prophylaxis of respiratory syncytial virus in Canada in 2003. (Q37481321) (← links)
• Respiratory syncytial virus prevention and therapy: Past, present, and future (Q37857806) (← links)
• Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection (Q38671952) (← links)
• Respiratory syncytial virus prevention in children with congenital heart disease: who and how? (Q39719279) (← links)
• Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan (Q40046043) (← links)
• Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants (Q40546134) (← links)
• Palivizumab for the prevention of respiratory syncytial virus infection (Q41855573) (← links)
• [Indications and prescription modalities of palivizumab in neonates] (Q81448212) (← links)
• Use of palivizumab in children with congenital heart disease (Q82284318) (← links)
• Antibody development for preventing the human respiratory syncytial virus pathology (Q92021897) (← links)
• La prévention de l’infection par le virus respiratoire syncytial (Q93485637) (← links)
• L’utilisation du palivizumab chez les enfants atteints d’une cardiopathie congénitale (Q93487046) (← links)